Changes in Red Blood Cell membrane lipid composition: A new perspective into the pathogenesis of PKAN-Reference-Cited by-同舟云学术

Changes in Red Blood Cell membrane lipid composition: A new perspective into the pathogenesis of PKAN

Published:2017-06 Issue:2 Volume:121 Page:180-189
ISSN:1096-7192
Container-title:Molecular Genetics and Metabolism
language:en
Short-container-title:Molecular Genetics and Metabolism

Author:

Aoun Manar,Corsetto Paola Antonia,Nugue Guillaume,Montorfano Gigliola,Ciusani Emilio,Crouzier David,Hogarth Penelope,Gregory Allison,Hayflick Susan,Zorzi Giovanna,Rizzo Angela Maria,Tiranti Valeria

Publisher

Elsevier BV

Subject

Endocrinology,Genetics,Molecular Biology,Biochemistry,Endocrinology, Diabetes and Metabolism

Reference54 articles.

1. Defective lipid metabolism in neurodegeneration with brain iron accumulation (NBIA) syndromes: not only a matter of iron;Colombelli;J. Inherit. Metab. Dis.,2015

3. Genetic, clinical, and radiographic delineation of Hallervorden–Spatz syndrome;Hayflick;N. Engl. J. Med.,2003

4. Clinical and genetic delineation of neurodegeneration with brain iron accumulation;Gregory;J. Med. Genet.,2009

5. An isoform of hPANK2, deficient in pantothenate kinase-associated neurodegeneration, localizes to mitochondria;Hörtnagel;Hum. Mol. Genet.,2003

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel mutations and molecular pathways identified in patients with brain iron accumulation disorders;neurogenetics;2023-07-15

2. Inherited Disorders of Coenzyme A Biosynthesis: Models, Mechanisms, and Treatments;International Journal of Molecular Sciences;2023-03-21

3. Comparison between Sickle Cell Disease Patients and Healthy Donors: Untargeted Lipidomic Study of Erythrocytes;International Journal of Molecular Sciences;2023-01-28

4. The red blood cell as a mediator of endothelial dysfunction in patients with familial hypercholesterolemia and dyslipidemia;Journal of Internal Medicine;2022-11-02

5. Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer;Clinical Lung Cancer;2022-11